Free Trial

Veracyte (VCYT) Competitors

$21.41
+0.03 (+0.14%)
(As of 06/18/2024 ET)

VCYT vs. GTH, BNR, PSNL, RDNT, GH, FTRE, VRDN, CDNA, CSTL, and FLGT

Should you be buying Veracyte stock or one of its competitors? The main competitors of Veracyte include Genetron (GTH), Burning Rock Biotech (BNR), Personalis (PSNL), RadNet (RDNT), Guardant Health (GH), Fortrea (FTRE), Viridian Therapeutics (VRDN), CareDx (CDNA), Castle Biosciences (CSTL), and Fulgent Genetics (FLGT).

Veracyte vs.

Veracyte (NASDAQ:VCYT) and Genetron (NASDAQ:GTH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

10.7% of Genetron shares are held by institutional investors. 1.3% of Veracyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Veracyte received 429 more outperform votes than Genetron when rated by MarketBeat users. Likewise, 72.93% of users gave Veracyte an outperform vote while only 33.33% of users gave Genetron an outperform vote.

CompanyUnderperformOutperform
VeracyteOutperform Votes
431
72.93%
Underperform Votes
160
27.07%
GenetronOutperform Votes
2
33.33%
Underperform Votes
4
66.67%

Veracyte has higher revenue and earnings than Genetron.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veracyte$361.05M4.53-$74.40M-$0.94-22.78
Genetron$94.34M1.35-$117.21MN/AN/A

Genetron has a net margin of 0.00% compared to Veracyte's net margin of -18.16%. Genetron's return on equity of 0.00% beat Veracyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Veracyte-18.16% -1.42% -1.33%
Genetron N/A N/A N/A

In the previous week, Veracyte had 5 more articles in the media than Genetron. MarketBeat recorded 5 mentions for Veracyte and 0 mentions for Genetron. Veracyte's average media sentiment score of 0.71 beat Genetron's score of 0.00 indicating that Veracyte is being referred to more favorably in the media.

Company Overall Sentiment
Veracyte Positive
Genetron Neutral

Veracyte currently has a consensus price target of $27.50, suggesting a potential upside of 28.44%. Given Veracyte's higher possible upside, analysts plainly believe Veracyte is more favorable than Genetron.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veracyte
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Genetron
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Veracyte has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500. Comparatively, Genetron has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500.

Summary

Veracyte beats Genetron on 11 of the 15 factors compared between the two stocks.

Get Veracyte News Delivered to You Automatically

Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VCYT vs. The Competition

MetricVeracyteMedical laboratories IndustryMedical SectorNASDAQ Exchange
Market Cap$1.64B$2.24B$5.10B$8.47B
Dividend YieldN/A2.07%5.34%4.10%
P/E Ratio-22.7820.96178.3118.01
Price / Sales4.53120.352,277.9265.63
Price / Cash225.94305.8731.3429.03
Price / Book1.504.054.844.26
Net Income-$74.40M-$128.24M$109.50M$215.55M
7 Day Performance-2.99%-4.30%-3.56%-2.17%
1 Month Performance-6.42%-9.46%-4.75%-3.84%
1 Year Performance-17.94%-18.74%-2.80%0.39%

Veracyte Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GTH
Genetron
0 of 5 stars
$4.03
+0.2%
N/A+43.7%$127.43M$94.34M0.00993High Trading Volume
BNR
Burning Rock Biotech
0 of 5 stars
$7.37
-4.4%
N/A-71.4%$78.98M$520.54M-1.141,138Positive News
PSNL
Personalis
4.0924 of 5 stars
$1.29
-5.9%
$5.00
+289.1%
-39.7%$66.74M$74.15M-0.68223News Coverage
RDNT
RadNet
3.197 of 5 stars
$58.50
+0.1%
$57.25
-2.1%
+85.9%$4.32B$1.62B195.0010,288Insider Selling
GH
Guardant Health
4.3426 of 5 stars
$30.50
+1.0%
$36.91
+21.0%
-19.3%$3.73B$563.95M-7.781,779Positive News
FTRE
Fortrea
2.8262 of 5 stars
$24.06
+0.4%
$32.30
+34.2%
N/A$2.15B$3.11B-17.3118,000
VRDN
Viridian Therapeutics
1.325 of 5 stars
$12.20
-1.9%
$32.00
+162.3%
-55.1%$778.60M$310,000.00-2.7194
CDNA
CareDx
2.7487 of 5 stars
$13.54
-4.6%
$16.50
+21.9%
+76.8%$705.16M$280.32M-3.96635Gap Down
CSTL
Castle Biosciences
2.4136 of 5 stars
$22.82
-0.4%
$31.00
+35.8%
+68.1%$632.75M$250.73M-19.84610Short Interest ↓
Positive News
FLGT
Fulgent Genetics
4.0157 of 5 stars
$19.52
+2.3%
$30.00
+53.7%
-47.2%$584.04M$289.21M-3.501,184Positive News

Related Companies and Tools

This page (NASDAQ:VCYT) was last updated on 6/19/2024 by MarketBeat.com Staff

From Our Partners